Overall survival among patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus chemotherapy in the ENGOT-EN6-NSGO/GOG-3031/RUBY Trial

IF 4.5 2区医学 Q1 OBSTETRICS & GYNECOLOGY

Gynecologic oncology Pub Date : 2024-10-09 DOI:10.1016/j.ygyno.2024.07.014

Matthew Powell , Annika Auranen , Lyndsay Willmott , Lucy Gilbert , Destin Black , David Cibula , Sudarshan Sharma , Giorgio Valabrega , Lisa Landrum , Lars Hanker , Ashley Stuckey , Ingrid Boere , Michael Gold , Mark Shahin , Bhavana Pothuri , Brian Slomovitz , Matthew Grimshaw , Shadi Stevens , Robert Coleman , Mansoor Mirza

引用次数: 0

查看原文本刊更多论文

ENGOT-EN6-NSGO/GOG-3031/RUBY试验中接受多司他单抗加化疗治疗的原发性晚期或复发性子宫内膜癌患者的总生存率

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Gynecologic oncology 医学-妇产科学

CiteScore

8.60

自引率

6.40%

发文量

1062

审稿时长

37 days

期刊介绍： Gynecologic Oncology, an international journal, is devoted to the publication of clinical and investigative articles that concern tumors of the female reproductive tract. Investigations relating to the etiology, diagnosis, and treatment of female cancers, as well as research from any of the disciplines related to this field of interest, are published. Research Areas Include: • Cell and molecular biology • Chemotherapy • Cytology • Endocrinology • Epidemiology • Genetics • Gynecologic surgery • Immunology • Pathology • Radiotherapy